Evidence map›Paper›PMID 27626703›Full record

ArticleOncotarget2016

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.

Nélida Inés Noguera, Maria Liliana Piredda, Riccardo Taulli, Gianfranco Catalano, Giulia Angelini, Girish Gaur, Clara Nervi, Maria Teresa Voso, Andrea Lunardi, Pier Paolo Pandolfi and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2020
    Review
  10. Article
  11. Review
  12. Biomodulatory Treatment With Azacitidine, All-Frontiers in pharmacology · 2018
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Nélida Inés NogueraDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Maria Liliana PireddaDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Riccardo TaulliCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Gianfranco CatalanoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Giulia AngeliniNeuro-Oncohematology Unit, Santa Lucia Foundation, Rome, Italy.
Girish GaurNeuro-Oncohematology Unit, Santa Lucia Foundation, Rome, Italy.
Clara NerviDepartment of Medical and Surgical Sciences and Biotechnologies, University of Roma "La Sapienza", Rome, Italy.
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Andrea LunardiCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Pier Paolo PandolfiCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Francesco Lo-CocoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Fondazione Santa Lucia · ITBeth Israel Deaconess Medical Center · USUniversity of Rome Tor Vergata · ITSapienza University of Rome · IT

Funding

PTEN IN ONTOGENESIS AND TUMOR SUPPRESSIONR01CA082328 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PANDOLFI, PIER PAOLO · 1999 to 2015
$5.3M
NCI NIH HHS R01 CA082328
6 · The paper itself

Abstract

Acute promyelocitic leukemia (APL) is characterized by the pathognomonic presence in leukemic blasts of the hybrid protein PML/RARA, that acts as a transcriptional repressor impairing the expression of genes that are critical to myeloid differentiation. Here, we show that primary blasts from APL patients express lower levels of the oncosuppressor protein PTEN, as compared to blast cells from other AML subtypes or normal bone marrow, and demonstrate that PML-RARA directly inhibits PTEN expression. We show that All-Trans Retinoic Acid (ATRA) triggers in APL cells an active chromatin status at the core regulatory region of the PTEN promoter, that allows the binding of the myeloid-regulating transcription factor PU.1, and, in turn, the transcriptional induction of PTEN. ATRA, via PML/RARA degradation, also promotes PTEN nuclear re-localization and decreases expression of the PTEN target Aurora A kinase. In conclusion, our findings support the notion that PTEN is one of the primary targets of PML/RARA in APL.

Indexed as

Gene Expression Regulation, NeoplasticHumansLeukemia, Promyelocytic, AcuteOncogene Proteins, FusionProto-Oncogene ProteinsProto-Oncogene Protein Spi-1PTEN PhosphohydrolaseTrans-ActivatorsTranscriptional ActivationOncogene Proteins, Fusionpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinProto-Oncogene ProteinsProto-Oncogene Protein Spi-1PTEN PhosphohydrolasePTEN protein, humanTrans-ActivatorsoncosuppressorPML-RARAPTENPU.1

Identifiers

PMID27626703
PMCPMC5341808
OpenAlexW2511021411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.